Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Insulin sensitivity during combined androgen blockade for prostate cancer.

Smith MR, Lee H, Nathan DM.

J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8. Epub 2006 Jan 24.

PMID:
16434464
2.

Changes in body composition during androgen deprivation therapy for prostate cancer.

Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW.

J Clin Endocrinol Metab. 2002 Feb;87(2):599-603.

PMID:
11836291
3.

Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.

Smith MR, Lee H, Fallon MA, Nathan DM.

Urology. 2008 Feb;71(2):318-22. doi: 10.1016/j.urology.2007.08.035.

4.

Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.

Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, Finkelstein JS.

Cancer. 2008 May 15;112(10):2188-94. doi: 10.1002/cncr.23440.

5.

Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

Hvid T, Winding K, Rinnov A, Dejgaard T, Thomsen C, Iversen P, Brasso K, Mikines KJ, van Hall G, Lindegaard B, Solomon TP, Pedersen BK.

Endocr Relat Cancer. 2013 Aug 19;20(5):621-32. doi: 10.1530/ERC-12-0393. Print 2013 Oct.

6.

Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.

Harrington JM, Schwenke DC, Epstein DR, Bailey DE Jr.

Oncol Nurs Forum. 2014 Jan 1;41(1):21-9. doi: 10.1188/14.ONF.21-29.

7.

Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.

Galv√£o DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R.

BJU Int. 2008 Jul;102(1):44-7. doi: 10.1111/j.1464-410X.2008.07539.x. Epub 2008 Mar 11. Erratum in: BJU Int. 2008 Aug;102(3):418.

8.

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.

Keating NL, O'Malley AJ, Smith MR.

J Clin Oncol. 2006 Sep 20;24(27):4448-56.

PMID:
16983113
9.

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.

Basaria S.

J Androl. 2008 Sep-Oct;29(5):534-9. doi: 10.2164/jandrol.108.005454. Epub 2008 Jun 20. Review.

10.

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

Conteduca V, Di Lorenzo G, Tartarone A, Aieta M.

Crit Rev Oncol Hematol. 2013 Apr;86(1):42-51. doi: 10.1016/j.critrevonc.2012.09.008. Epub 2012 Oct 23. Review.

PMID:
23092636
11.

Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control.

Ziaran S, Goncalves FM, Breza J Sr.

World J Urol. 2013 Apr;31(2):289-92. doi: 10.1007/s00345-012-0926-x. Epub 2012 Aug 17.

PMID:
22898989
12.

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition.

Smith MR, Goode M, Zietman AL, McGovern FJ, Lee H, Finkelstein JS.

J Clin Oncol. 2004 Jul 1;22(13):2546-53.

PMID:
15226323
13.

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Shahani S, Braga-Basaria M, Basaria S.

J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18. Review.

PMID:
18349064
14.

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, Reimondo G, Mari M, Ardissone P, De Luca S, Fasolis G, Fontana D, Rossetti SR, Angeli A; Gruppo Onco Urologico Piemontese (G.O.U.P.), Rete Oncologica Piemontese..

J Urol. 2002 Jun;167(6):2361-7; discussion 2367.

PMID:
11992038
15.

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

Smith MR, Fallon MA, Goode MJ.

Urology. 2003 Jan;61(1):127-31.

PMID:
12559282
16.

The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.

Yannucci J, Manola J, Garnick MB, Bhat G, Bubley GJ.

J Urol. 2006 Aug;176(2):520-5.

PMID:
16813881
17.

Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.

Cheung AS, Hoermann R, Dupuis P, Joon DL, Zajac JD, Grossmann M.

Eur J Endocrinol. 2016 Sep;175(3):229-37. doi: 10.1530/EJE-16-0200. Epub 2016 Jun 23.

PMID:
27340081
18.
19.

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.

J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7. Epub 2005 Sep 27.

PMID:
16189261

Supplemental Content

Support Center